Core Insights - The article highlights the transformation of Jia Bi You Biotechnology (Wuhan) Co., Ltd. from a single nutrient supplier to a synthetic biology platform enterprise over six years since its listing on the Sci-Tech Innovation Board, marking a significant milestone in China's food biotechnology sector [1] Financial Performance - Jia Bi You's revenue has grown from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate (CAGR) of 12.2% [2] - In 2025, the company reported a revenue of 428 million yuan and a net profit of 129 million yuan in the first three quarters, reflecting a year-on-year increase of 54.18%, surpassing the total net profit for 2024 [2] - As of December 19, 2025, the company's market capitalization exceeded 3.9 billion yuan, demonstrating significant growth since its initial public offering [2] Product Development and Market Position - The company has expanded its product matrix, achieving over 40% global market share in ARA (Arachidonic Acid) and surpassing 100 million yuan in annual sales for DHA (Docosahexaenoic Acid) [2] - Jia Bi You has developed a diverse product system covering human nutrition, animal nutrition, and personal care, with 114 authorized products for SA (Sialic Acid) [2] - The successful mass production of 2'-fucosyllactose (2'-FL) in 2025 fills a significant gap in China's HMO (Human Milk Oligosaccharides) market [2] Supply Chain and Risk Management - The company has established a fully controllable supply chain, achieving domestic substitution across the entire production process from strain cultivation to fermentation and product application [3] - The second phase of the Wuhan production base has positioned the company among the global leaders in ARA and DHA production capacity [3] - Jia Bi You's products have received international certifications and are exported to over 30 countries, establishing stable partnerships with global giants like Nestlé [3] Research and Development - Jia Bi You maintains a research and development investment of over 8%, with 2024 R&D expenditure reaching 47.9 million yuan, a 24.12% increase year-on-year [4] - The company has developed a full-stack technology loop integrating AI and synthetic biology, breaking foreign monopolies in industrial strains [4] - The establishment of a national pilot platform for microbial fermentation supports the transition from laboratory to production line [4] Industry Standards and Future Strategy - Jia Bi You has actively participated in the formulation of national food safety standards and was selected for the national synthetic biology standardization project research group in 2025 [5] - The company aims to focus on high-end equipment development and advanced molecular layout, targeting the trillion-yuan market outlined in the 14th Five-Year Plan [5] - Future plans include upgrading the pilot platform to a public service hub for bio-manufacturing and deepening global cooperation to expand into European, American, and Southeast Asian markets [5]

Core Insights - The article emphasizes the strategic importance of biomanufacturing, which is projected to create a $30 trillion market, comparable to the significance of chip manufacturing [3] - Biomanufacturing is not merely a replacement for traditional chemical processes but a transformative engine that redefines the underlying logic of industries, impacting the entire supply chain from raw materials to end products [3][4] Company Overview - Jia Bi You has been proactive in the biomanufacturing sector, establishing a robust business model that has evolved significantly since its listing on the STAR Market six years ago [4] - The company reported a revenue increase from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate of 12.2% [4] Market Positioning - The implementation of new national standards for infant formula in February 2023 has created a favorable market environment for Jia Bi You, allowing it to efficiently release production capacity [10] - The expiration of DSM's core patents has enabled Jia Bi You to penetrate international markets and establish stable partnerships with major companies like Nestlé and Danone [12] Strategic Growth - Jia Bi You's revenue structure has diversified, with the human nutrition segment's share decreasing from over 95% to around 80%, while the health sector now contributes nearly 20% [13] - The company maintains a high R&D investment rate of 8%-10%, which has supported its innovation and technological advancements [15] Technological Innovation - The company has developed a comprehensive technology system based on synthetic biology, which includes bioinformatics, AI, and other interdisciplinary fields [15][16] - Jia Bi You aims to leverage AI to enhance its research and application processes, creating a specialized biological database to optimize product development and personalized nutrition solutions [18][19] International Expansion - Jia Bi You's international revenue share has increased from less than 10% to nearly 40%, with products now available in over 30 countries [24] - The company adopts a flexible internationalization strategy, focusing on technology cooperation and customized supply rather than aggressive expansion [25] ESG Commitment - Jia Bi You places significant emphasis on ESG practices, having initiated social responsibility reports since 2019 and implementing sustainable practices such as replacing coal boilers with natural gas [27][28] - The company has received recognition for its ESG efforts, highlighting its commitment to environmental, social, and governance standards [30] Future Opportunities - The upcoming "15th Five-Year Plan" presents multiple opportunities for Jia Bi You, including favorable policies for biomanufacturing and increased demand for infant nutrition products [33][34] - The company believes that its internal capabilities and technological advancements will be the primary drivers of growth, rather than external trends [35]

Core Insights - Company has focused on emerging products such as SA (Sialic Acid) and HMOs (Human Milk Oligosaccharides) while maintaining its core product line [1][2] - The company reported a revenue of 430 million yuan for the first three quarters of 2025, a year-on-year increase of 10.56%, and a net profit of 130 million yuan, up 54.18% year-on-year, indicating a significant profit growth outpacing revenue growth [1] - The company aims to expand its market presence in infant formula, animal nutrition, and personal care sectors through a strategy termed "one main and two wings" [1][2] Company Strategy - The company is enhancing its product offerings in the infant formula market by promoting algal oil DHA as a substitute for fish oil DHA and deepening cooperation on HMOs [2] - In the pet nutrition sector, the company employs a strategy of "technology research + brand marketing + supply chain management" to enhance product innovation and competitiveness [3] - In the beauty and personal care sector, the company leverages synthetic biology and innovative technologies to rapidly screen and validate new cosmetic raw materials [3] Market Position - The company is a leader in the microbial synthesis nutrient sector in China, with key products including ARA, DHA, and β-carotene, widely used in infant formula, health foods, animal nutrition, and personal care [1] - The domestic and international milk powder markets continue to provide favorable conditions for the company's stable performance [1] - The approval of HMOs as new raw materials for infant formula by the National Health Commission is expected to accelerate the application of these products in the infant nutrition sector [2]

Group 1 - The company, Jia Bi You, announced that its Q3 2025 earnings briefing is scheduled for December 15, 2025 [1]

证券代码：688089 证券简称：嘉必优 公告编号：2025-084 嘉必优生物技术（武汉）股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 嘉必优生物技术（武汉）股份有限公司(以下简称"公司")已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 15 日（星期 一）14:00-15:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交 流。 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 12 月 15 日（星期一） ...

Group 1 - The company, Jia Bi You, stated on December 4 that it aims to ensure all investors receive information equally by disclosing the total number of shareholders in its regular reports, in accordance with information disclosure regulations [2]

Group 1 - The company has approved a second phase of share repurchase using its own funds and special loans, with a total repurchase amount between RMB 15 million and RMB 30 million, and a maximum repurchase price of RMB 25.00 per share, valid for up to 12 months from the board's approval date [1] - The maximum repurchase price was adjusted to RMB 24.80 per share effective July 10, 2025, due to the implementation of the 2024 annual equity distribution [2] - The maximum repurchase price was further adjusted to RMB 35.00 per share effective September 9, 2025, following a board resolution [2] Group 2 - As of November 30, 2025, the company has repurchased a total of 1,060,573 shares, representing 0.63% of the total share capital, with a total transaction amount of RMB 27,921,296.05, and the highest and lowest transaction prices being RMB 28.58 and RMB 23.52 per share, respectively [3] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [4]

格隆汇12月1日丨嘉必优(688089.SH)公布，截至2025年11月30日，公司通过上海证券交易所交易系统以 集中竞价交易方式累计回购公司股份106.06万股，占公司总股本的比例为0.63%，最高成交价为28.58元/ 股，最低成交价为23.52元/股，累计成交总金额为2792.13万元（不含印花税、交易佣金等交易费用）。 ...

一、回购股份的基本情况 2025 年 1 月 24 日，公司召开第四届董事会第二次会议，审议通过了《关于 第二期以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金 和回购专项贷款以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股） 股票，并在未来适宜时机用于实施股权激励计划，回购资金总额不低于人民币 1,500 万元（含），不超过人民币 3,000 万元（含），回购价格不超过 25.00 元/股 （含），回购股份的期限为自公司董事会审议通过本次回购方案之日起不超过 12 个 月 。 具 体 内 容 详 见 公 司 于 2025 年 2 月 7 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）上披露的《嘉必优生物技术（武汉）股份有限公司关于第二 期以集中竞价交易方式回购公司股份的回购报告书》（公告编号：2025-008）。 证券代码：688089 证券简称：嘉必优 公告编号：2025-083 嘉必优生物技术（武汉）股份有限公司 关于第二期以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并 ...

Core Insights - The Ministry of Industry and Information Technology of China has officially released the first batch of the "Biomanufacturing Pilot Capability Construction Platform List," with Jia Bi You Biotechnology (Wuhan) Co., Ltd. being recognized for its strong technological foundation and industrial application capabilities in biomanufacturing [1][2] - Biomanufacturing has been elevated to a national strategic level, identified as a key growth point in the "14th Five-Year Plan," and is expected to play a crucial role in supporting China's dual carbon goals and green transformation [2][6] - Jia Bi You is positioned as a "full-chain player" in the biomanufacturing sector, having successfully industrialized key nutritional ingredients and expanded its product line to include high-value items such as DHA and HMOs [3][6] Industry Context - The emphasis on biomanufacturing in the "14th Five-Year Plan" reflects the need for China to enhance its economic structure and address global industrial competition, particularly in high-value areas like green manufacturing and functional molecules [2][4] - The selection of "symbolic projects" by regulatory authorities aims to identify companies that can represent China's competitiveness in high-end nutritional raw materials and green manufacturing [2][4] Company Developments - Jia Bi You has been recognized for its innovative capabilities, having its product 2'-fucosyllactose (2'-FL) selected as a "symbolic product" in biomanufacturing, alongside its inclusion in the high-performance bioreactor innovation list [3][6] - The company is actively implementing an "AI + synthetic biology" strategy, enhancing its research and manufacturing processes through automation and advanced technologies [4][5] - Jia Bi You has established an intelligent research platform and is developing proprietary computational tools to optimize its biomanufacturing processes, significantly improving efficiency and product quality [5][6] Strategic Positioning - Jia Bi You is strategically aligned with national policies, having developed a platform-based approach that integrates AI and synthetic biology to enhance its production capabilities [7][8] - The company has proactively engaged in regional industrial planning, positioning itself to benefit from favorable policies and market opportunities in the biomanufacturing sector [7][8]